Project : MFA011
Indication : Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | |
|---|---|---|---|---|---|
MMB101 is a humanized anti-TIGIT monoclonal antibody designed to target a novel epitope
spanning multiple PVR binding sites for optimized functional coverage.
Project : MMB102
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
MMB102 is a GITR agonistic antibody designed to achieve an anti-cancer immune response via deactivation of immuno-suppressive Treg cells and activation of CD8+ effector T cells.
Project : MFA011
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
MFA011 is a fusion antibody with MediMabBio’s proprietary anti-TIGIT antibody and IL15 cytokines.
Project : MFA021
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
Project : MMB301
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
| Pipeline | Indication | Modality | Discovery | Lead Optimization | Preclinical Efficacy | IND-enabling |
|---|---|---|---|---|---|---|
| MediLink™ Programs | ||||||
| MFA011 | Oncology | Fusion Ab | ||||
| MFA031 | Autoimmune Diseases, Transplantation |
Fusion Ab | ||||
| MFA041 | Autoimmune Diseases | Fusion Ab | ||||
| Platforms | ||||||
| MediLink™ Platform |
Cancer, Autoimmune Diseases |
Fusion Ab | ||||
| MediKine™ Platform |
Cancer, Autoimmune Diseases |
Fusion Ab | ||||